与未经治疗的晚期非小细胞肺癌患者对联合免疫疗法的长期反应相关的预测因素:多中心回顾性研究
Kei Sonehara1, Ryota Ozawa2, Mineyuki Hama3
1First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Oncology
|July 9, 2023
概括
鉴定了高级非小细胞肺癌 (NSCLC) 组合免疫治疗的长期反应预测因素. 反应性C蛋白/白蛋白比率 (CAR) 和最佳客观反应是预测治疗结果的有希望的生物标志物.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 生物标志物研究 生物标志物研究
背景情况:
- 组合免疫疗法是高级非小细胞肺癌 (NSCLC) 的标准一线治疗方法.
- 对这种治疗的长期反应的预测因素仍未得到充分研究.
- 识别这些因素对于优化患者选择和治疗策略至关重要.
研究的目的:
- 为了比较临床发现,包括系统性炎症营养生物标志物,响应者和不响应者之间的复合免疫疗法在先进的NSCLC.
- 调查与长期反应和整体存活率 (OS) 相关的预测因素.
主要方法:
- 分析了接受组合免疫治疗的112名晚期NSCLC患者的队列.
- 受访者被定义为实现至少9个月的无进展生存.
- 进行了统计分析,以评估长期响应和生存状况的预测因素.
主要成果:
- 与非响应者 (n=58) 相比,响应者 (n=54) 的年龄明显较小,预后营养指数较高,C反应蛋白/白蛋白比率 (CAR) 较低.
- 中央共和国证明了0.691曲线下的面积,最佳切线为0.215.
- 多变量分析确定了CAR和最佳客观反应作为有利的OS的独立预测指标.
结论:
- 建议C-反应蛋白/白蛋白比率 (CAR) 和最佳客观反应作为接受组合免疫治疗的NSCLC患者长期反应的有价值预测指标.
- 这些生物标志物可能有助于对患者进行分层,以获得最佳治疗结果.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.6K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.0K
相关概念视频
Tumor Immunotherapy
573
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Vaccines
428
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
428
